6/19/2025

Source: SeekingAlpha

6/18/2025

Charles River Laboratories’s stock price has taken a beating over the past six months, shedding 20.8% of its value and falling to $145.05 per share. This may have investors wondering how to approach the situation.

Source: Yahoo

6/17/2025

Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors

Source: MarketWatch

6/17/2025

WILMINGTON - Charles River Laboratories International, Inc. today announced a recycling program, developed in partnership with international recycling leader TerraCycle, to give new life to...

Source: Finnhub

6/17/2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Source: Yahoo

6/17/2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Fortrea (NASDAQ:FTRE) and its peers.

Source: Yahoo

6/17/2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest of the drug development inputs & services stocks fared in Q1.

Source: Yahoo

6/16/2025

Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors despite daily gains

Source: MarketWatch

6/16/2025

WILMINGTON, Mass., June 16, 2025--Charles River today announced a recycling program, developed in partnership with TerraCycle to give new life to single-use plastic cartridges.

Source: Yahoo

6/13/2025

Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors

Source: MarketWatch

6/13/2025

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns. See why I rate ABCL stock as a Hold.

Source: SeekingAlpha

6/11/2025

Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 2.7% year on year to $984.2 million. Its non-GAAP profit of $2.34 per share was 12.8% above analysts’ consensus estimates.

Source: Yahoo

6/10/2025

Megacap stocks aren’t all up in 2025. But this chart shows they’ve trounced the S&P 500’s smallest equities.

Source: MarketWatch

6/9/2025

Presenter SpeechMax Smock All right. Good morning, everyone, and thanks for joining us for the management presentation. My name is Max Smock, and I'm the research analyst here at William Blair, who...

Source: Finnhub

6/6/2025

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

6/6/2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Source: Yahoo

6/4/2025

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

6/4/2025

Presenter SpeechDavid Windley Hi. Good morning. I'm Dave Windley with Jefferies Healthcare Equity Research. Welcome to Jefferies 2025 New York Conference. Pleased to have you here. I appreciate the...

Source: Finnhub

6/4/2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and worst performers in the drug development inputs & services industry.

Source: Yahoo

6/3/2025

William Blair 45th Annual Growth Stock Conference June 3, 2025 Flavia Pease Executive Vice President & Chief Financial Officer ...

Source: Finnhub